Scientific and clinical progress together with the development of effective novel therapeutic
options has engendered multiple important changes in the diagnosis and management of …

These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP),
representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the …

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and
effective therapy are critical. This revision and update of the global WAO/EAACI guideline on …

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and
appropriate therapy are essential. This update and revision of the global guideline for HAE …

Importance Current treatments for long-term prophylaxis in hereditary angioedema have
limitations. Objective To assess the efficacy of lanadelumab, a fully human monoclonal …

This is an update to the 2014 Canadian Hereditary Angioedema Guideline with an
expanded scope to include the management of hereditary angioedema (HAE) patients …

Angioedema is defined as localized and self‐limiting edema of the subcutaneous and
submucosal tissue, due to a temporary increase in vascular permeability caused by the …

Hereditary Angioedema Hereditary angioedema is a rare genetic disease that may include
recurrent attacks of cutaneous angioedema, severe abdominal pain, and airway …

Background Hereditary angioedema is a disabling, potentially fatal condition caused by
deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use …

Background The consensus documents published to date on hereditary angioedema with
C1 inhibitor deficiency (C1‐INH‐HAE) have focused on adult patients. Many of the previous …